Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
NICOX SA
Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment
July 1, 2026
Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
June 18, 2026
Reminder: Nicox June 2024 Warrants will expire June 19, 2026
June 8, 2026
Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative
June 3, 2026
Nicox Provides Full Year 2025 Financial Results and Corporate Update
April 30, 2026
Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026
April 20, 2026
Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026
February 10, 2026
Nicox annonce sa participation à des congrès au premier semestre 2026 et la présentation prochaine de données scientifiques
January 20, 2026